Staccato Alprazolam vs Stiripentol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Staccato Alprazolam

Developed by UCB and partners

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT03478982 · Phase 2 · completed

The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.

Next expected readout: March 2027 · NCT05077904 (registry estimate)

Reported efficacy

Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)

Result source: NCT03478982

Stiripentol

Marketed by Biocodex

Approved in Epilepsysmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointStaccato AlprazolamStiripentol
Seizure frequency, % change—Trial running · NCT05076617—Not reported
50% responder rate—Trial running · NCT05076617—Not reported
Seizure freedom—Trial running · NCT05076617—Not reported

Seizure frequency, % change

Staccato Alprazolam
—Trial running · NCT05076617
Stiripentol
—Not reported

50% responder rate

Staccato Alprazolam
—Trial running · NCT05076617
Stiripentol
—Not reported

Seizure freedom

Staccato Alprazolam
—Trial running · NCT05076617
Stiripentol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Stiripentol: no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Staccato Alprazolam: 3 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricStaccato Alprazolam
Dropout rate
0%2.0 mga
NCT03478982 · Phase 2
show 2 more results
0%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Discontinued due to AEs
—2.0 mga
NCT03478982 · Phase 2
show 2 more results
—1.0 mg
NCT03478982 · Phase 2
—1.0 mg
NCT03478982 · Phase 2
Serious AEs
0%2.0 mga
NCT03478982 · Phase 2
show 2 more results
2.6%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Most frequent reported AEs
2.0 mga
cough 18.4% (placebo 0%)
dysgeusia 10.5% (placebo 2.5%)
somnolence 10.5% (placebo 2.5%)
NCT03478982 · Phase 2
show 2 more results
1.0 mg
somnolence 18.4% (placebo 2.5%)
dysgeusia 15.8% (placebo 2.5%)
cough 10.5% (placebo 0%)
NCT03478982 · Phase 2
1.0 mg
cough 12.5% (placebo 0%)
dysmenorrhoea 12.5% (placebo 0%)
gastroenteritis viral 12.5% (placebo 0%)
NCT03478982 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Staccato Alprazolam

Seizure Cessation 2min no Recurrence 2 h 65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
62.5% (n=8) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Rescue Medication Use 7.9% (n=38) vs 7.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
0% (n=8) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
15.8% (n=38) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Secondary Generalization 0% (n=38) vs 0% (n=40) placebo @ 0.14wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
12.5% (n=8) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2
0% (n=38) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Staccato Alprazolam's landscape · Stiripentol's landscape